MTOR and metabolic dysfunction-associated steatotic liver disease: The mammalian target of the rapamycin (mTOR) pathway is coupled to the insulin/IGF-1 signaling pathway; thus, NAFLD has a high probability of occurring due to hyperinsulinemia [22].